XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition
 9 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition During the three and nine months ended September 30, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $83,000 and $1.3 million, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $21,000 and $167,000, respectively, from AstraZeneca and $132,000 and $364,000, respectively, from various other contracts. Of the total revenue recognized during the three and nine months ended September 30, 2020, $4,000 and $127,000, respectively, were in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.